RSS

Juluca

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir/rilpivirine) — a two-drug regimen, once-daily, single pill for the treatment of HIV-1. more

News

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Juluca treatment for HIV-1. more

News

The US Food and Drug Administration (FDA) has approved the first two-drug regimen for certain patients with human immunodeficiency virus type 1 (HIV-1). more

News